^
Association details:
| Biomarker: | FAT1 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
Published date:
06/23/2022
Excerpt:
In the pooled melanoma cohort, univariate survival analysis revealed that patients with FAT1 mutations had a significantly improved ICI prognosis than those wild-type patients (median survival time: 41.9 vs. 25.6 months, Log-rank test P = 0.013; Fig. 2a)....Further analysis showed that FAT1 mutated patients also exhibited an elevated ICI response rate (43.2% vs. 29.2%, Fisher exact test P = 0.014; Fig. 2c). And this result was still significant after adjusting for other confounding factors (OR: 0.58, 95% CI: 0.35–0.96, P = 0.032; Fig. 2d).
DOI:
https://doi.org/10.1038/s41698-022-00292-6
